Author details

Full Name

John A Copland

Affiliation

Mayo Clinic Jacksonville

ORCID

Career Start Year

1982

Papers

139

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37919223	Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.	Surgery	2024
37919223	Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.	Surgery	2024
37208334	ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.	Nat Commun	2023
37568667	The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth.	Cancers (Basel)	2023
37964967	CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.	Front Endocrinol (Lausanne)	2023
37409698	Radiosynthesis and Preliminary Evaluation of [<sup>11</sup>C]SSI-4 for the Positron Emission Tomography Imaging of Stearoyl CoA Desaturase 1.	Mol Pharm	2023
37208334	ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.	Nat Commun	2023
37964967	CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.	Front Endocrinol (Lausanne)	2023
37568667	The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth.	Cancers (Basel)	2023
37409698	Radiosynthesis and Preliminary Evaluation of [<sup>11</sup>C]SSI-4 for the Positron Emission Tomography Imaging of Stearoyl CoA Desaturase 1.	Mol Pharm	2023
35326513	The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer.	Cancers (Basel)	2022
36048524	Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.	Clin Cancer Res	2022
35499760	Targeting BCAT1 Combined with Î±-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma.	Cancer Res	2022
35680531	Complete response in Patients With Lung-Only Metastatic Prostate Cancer: Outcome Analysis.	Clin Genitourin Cancer	2022
35405742	YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase IIÎ± at the ATP-Binding Site.	Mol Cancer Ther	2022
35326513	The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer.	Cancers (Basel)	2022
35680531	Complete response in Patients With Lung-Only Metastatic Prostate Cancer: Outcome Analysis.	Clin Genitourin Cancer	2022
35405742	YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase IIÎ± at the ATP-Binding Site.	Mol Cancer Ther	2022
35499760	Targeting BCAT1 Combined with Î±-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma.	Cancer Res	2022
36048524	Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.	Clin Cancer Res	2022
33406440	Stearoyl-CoA Desaturase-Mediated Monounsaturated Fatty Acid Availability Supports Humoral Immunity.	Cell Rep	2021
34078650	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).	Clin Cancer Res	2021
33669447	Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.	Int J Mol Sci	2021
33567529	Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.	Cancers (Basel)	2021
33766079	Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.	Breast Cancer Res	2021
33406440	Stearoyl-CoA Desaturase-Mediated Monounsaturated Fatty Acid Availability Supports Humoral Immunity.	Cell Rep	2021
33766079	Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.	Breast Cancer Res	2021
33567529	Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.	Cancers (Basel)	2021
33669447	Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.	Int J Mol Sci	2021
34078650	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).	Clin Cancer Res	2021
31575656	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i>.	Mol Cancer Ther	2020
32123665	Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus.	Urol Case Rep	2020
31575656	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth <i>In Vivo</i>.	Mol Cancer Ther	2020
32480094	3D porous chitosan-chondroitin sulfate scaffolds promote epithelial to mesenchymal transition in prostate cancer cells.	Biomaterials	2020
31860772	Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry.	J Mass Spectrom	2020
33027969	A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor.	Biomolecules	2020
32564377	Correlation of novel ALK<sup>ATI</sup> with ALK immunohistochemistry and clinical outcomes in metastatic melanoma.	Histopathology	2020
33109627	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.	ESMO Open	2020
31860772	Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry.	J Mass Spectrom	2020
33109627	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.	ESMO Open	2020
33027969	A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor.	Biomolecules	2020
32123665	Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus.	Urol Case Rep	2020
32564377	Correlation of novel ALK<sup>ATI</sup> with ALK immunohistochemistry and clinical outcomes in metastatic melanoma.	Histopathology	2020
32480094	3D porous chitosan-chondroitin sulfate scaffolds promote epithelial to mesenchymal transition in prostate cancer cells.	Biomaterials	2020
30696657	Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.	Cancer Res	2019
30696657	Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.	Cancer Res	2019
31279100	3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines.	Biomaterials	2019
31076001	Aberrant lipid metabolism as a therapeutic target in liver cancer.	Expert Opin Ther Targets	2019
30737244	Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.	Clin Cancer Res	2019
31279100	3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines.	Biomaterials	2019

1 - 50 of 278

Hui Xue

Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences

Career Start Year 2005

Number of shared co-authors 1

Xiaohu Zhang

National Center for Advancing Translational Sciences

Career Start Year 2003

Number of shared co-authors 1

Anupama E Gururaj

National Institute of Allergy and Infectious Disease, National Institutes of Health

Career Start Year 2002

Number of shared co-authors 1

Kristiina Iljin

VTT Technical Research Centre of Finland Ltd

Career Start Year 1999

Number of shared co-authors 2

Krishna P Bhat

Department of Neurosurgery at the University of Texas MD Anderson Cancer Center

Career Start Year 1998

Number of shared co-authors 0

Theresa M LaVallee

Parker Institute for Cancer Immunotherapy

Career Start Year 1996

Number of shared co-authors 0

John D Gordan

Quantitative Biosciences Institute (QBI), University of California San Francisco

Career Start Year 1996

Number of shared co-authors 0

Paul N Span

Radboud University Medical Center

Career Start Year 1993

Number of shared co-authors 1

Barry R Davies

Oncology R&D

Career Start Year 1992

Number of shared co-authors 1

Rosemarie Schmandt

The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center

Career Start Year 1991

Number of shared co-authors 4

Anil K Sood

The University of Texas MD Anderson Cancer Center

Career Start Year 1991

Number of shared co-authors 6

Aykut Uren

Georgetown University Medical Center

Career Start Year 1991

Number of shared co-authors 1

Thomas J Giordano

University of Michigan ann arbor

Career Start Year 1989

Number of shared co-authors 4

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 5

Enzo Medico

Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS

Career Start Year 1988

Number of shared co-authors 1

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 2

Francesco Caiazza

Department of Pharmaceutical Chemistry, University of California san francisco

Career Start Year 1987

Number of shared co-authors 0

Cuong Hoang-Vu

Center for Cancer Research, National Cancer Institute

Career Start Year 1985

Number of shared co-authors 5

Massimo Loda

Weill Medical College of Cornell University

Career Start Year 1984

Number of shared co-authors 1

Andrew D Cherniack

Dana-Farber Cancer Institute

Career Start Year 1984

Number of shared co-authors 9

David D L Bowtell

Peter MacCallum Cancer Centre

Career Start Year 1983

Number of shared co-authors 11

Alan Ashworth

UCSF Helen Diller Family Comprehensive Cancer Center

Career Start Year 1982

Number of shared co-authors 2

Edison T Liu

USA The Jackson Laboratory Cancer Center

Career Start Year 1982

Number of shared co-authors 3

Adrian L Harris

University of Oxford

Career Start Year 1981

Number of shared co-authors 1

David M Thomas

Garvan Institute of Medical Research

Career Start Year 1980

Number of shared co-authors 3

Francisca Vazquez

Broad Institute of MIT and Harvard

Career Start Year 1979

Number of shared co-authors 1

Christopher C Benz

Buck Institute for Research on Aging

Career Start Year 1977

Number of shared co-authors 10

Gordon B Mills

Knight Cancer Institute, Oregon Health and Sciences University

Career Start Year 1976

Number of shared co-authors 15

William E Grizzle

University of Alabama at Birmingham

Career Start Year 1974

Number of shared co-authors 2

Anna DeFazio

Westmead Hospital

Career Start Year 1972

Number of shared co-authors 9

row(s) 1 - 30 of 30

Robert C Smallridge

Mayo Clinic School of Medicine, Mayo Clinic

Co-authored papers 24

Vera J Suman

Mayo Clinic

Co-authored papers 8

Liewei Wang

Mayo Clinic

Co-authored papers 5

Richard M Weinshilboum

Mayo Clinic

Co-authored papers 5

Judy C Boughey

Mayo Clinic

Co-authored papers 5

Matthew P Goetz

Mayo Clinic

Co-authored papers 5

Clive S Grant

Inova Health System

Co-authored papers 4

Richard R Drake

Medical University of South Carolina

Co-authored papers 4

James N Ingle

Mayo Clinic

Co-authored papers 4

Bo Qin

Co-authored papers 3

Richard W Joseph

Mayo Clinic Hospital

Co-authored papers 3

Robert L Foote

Mayo Clinic

Co-authored papers 2

Daniel D Von Hoff

Co-authored papers 2

Lisa Zhang

National Institute of Child Health and Development

Co-authored papers 2

Electron Kebebew

Stanford University School of Medicine

Co-authored papers 2

Susan R Davis

Co-authored papers 2

Jean-Pierre A Kocher

Mayo Clinic

Co-authored papers 2

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Co-authored papers 2

Bo Gao

Crown Princess Mary Cancer Centre, Westmead Hospital

Co-authored papers 2

Myriem Boufraqech

The University of Texas at Austin

Co-authored papers 2

Amit Mehta

Center for Cancer Research, Maryland. Geisel School of Medicine at Dartmouth

Co-authored papers 2

Saravut J Weroha

Mayo Clinic